Compare CVS Health Corp (CVS) vs SPDR Gold Trust (GLD) Price & Performance

CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.

The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.

GLD trades at $398.47, up 2.26% in the past 24 hours, with a bullish technical signal driven by moving averages. The stock is near its pivot point of $399, with support at $397 and resistance at $400. Recent news highlights gold's rebound potential, citing central bank buying and softer Fed expectations as tailwinds. Financial ratios are unavailable, but the ETF's performance aligns with spot gold trends, which have gained momentum from geopolitical and macroeconomic factors.

The outlook for GLD is positive, with technical strength and supportive sentiment suggesting potential upside toward $402–$404 resistance. Risks include sensitivity to interest rate shifts and dollar strength, while analyst optimism centers on gold's safe-haven appeal. Investors should weigh ETF costs against physical gold alternatives, as momentum may hinge on sustained demand and economic data.